TP Therapeutics, Inc. (TP) is a structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. They focus on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. The company went public in 2019 and was acquired by Bristol Myers Squibb in 2022.